Found in transcription: gene expression and other novel blood biomarkers for the early detection of breast cancer

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J. Clin.55(2), 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• Berry DA, Cronin KA, Plevritis SK et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N. Engl. J. Med.353(17), 1784–1792 (2005).
   PubMed Web of Science ®Google Scholar
• Shen Y, Zelen M. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations. J. Clin. Oncol.19(15), 3490–3499 (2001).
   PubMed Web of Science ®Google Scholar
• Pisano ED, Gatsonis C, Hendrick E et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N. Engl. J. Med.353(17), 1773–1783 (2005).
   PubMed Web of Science ®Google Scholar
• Kriege M, Brekelmans CT, Boetes C et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N. Engl. J. Med.351(5), 427–437 (2004).
   PubMed Web of Science ®Google Scholar
• Warner E, Plewes DB, Hill KA et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA292(11), 1317–1325 (2004).
   PubMed Web of Science ®Google Scholar
• Leach MO, Boggis CR, Dixon AK et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet365(9473), 1769–1778 (2005).
   PubMed Web of Science ®Google Scholar
• Kuhl CK, Schrading S, Leutner CC et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J. Clin. Oncol.23(33), 8469–8476 (2005).
   PubMed Web of Science ®Google Scholar
• Sardanelli F, Podo F, D’Agnolo G et al. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology242(3), 698–715 (2007).
   PubMed Web of Science ®Google Scholar
• Sardanelli F, Podo F. Breast MR imaging in women at high-risk of breast cancer: is something changing in early breast cancer detection? Eur. Radiol.17(4), 873–887 (2007).
   PubMed Web of Science ®Google Scholar
• Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol.25(33), 5287–5312 (2007).
   PubMed Web of Science ®Google Scholar
• Maxwell PH, Dachs GU, Gleadle JM et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl Acad. Sci. USA94(15), 8104–8109 (1997).
   PubMed Web of Science ®Google Scholar
• Todorov P, Cariuk P, McDevitt T et al. Characterization of a cancer cachectic factor. Nature379(6567), 739–742 (1996).
   PubMed Web of Science ®Google Scholar
• Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am. J. Physiol. Cell Physiol.282(5), 947–970 (2002).
   PubMed Web of Science ®Google Scholar
• Dvorak HF. Tumors: wounds that do not heal: similarities between tumor stroma generation and wound healing. N. Engl. J. Med.315(26), 1650–1659 (1986).
   PubMed Web of Science ®Google Scholar
• Briegel KJ. Embryonic transcription factors in human breast cancer. IUBMB Life58(3), 123–132 (2006).
   PubMed Web of Science ®Google Scholar
• Croci DO, Zacarias Fluck MF, Rico MJ et al. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol. Immunother.56(11), 1687–1700 (2007).
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol.3(11), 991–998 (2002).
   PubMed Web of Science ®Google Scholar
• Jain A, Patil VP, Fung J. Incidence of de novo cancer and lymphoproliferative disorders after liver transplantation in relation to age and duration of follow-up. Liver Transpl.14(10), 1406–1411 (2008).
   PubMed Web of Science ®Google Scholar
• Bhowmick NA, Moses HL. Tumor–stroma interactions. Curr. Opin. Genet. Dev.15(1), 97–101 (2005).
   PubMed Web of Science ®Google Scholar
• Kim JB, Stein R, O’Hare MJ. Tumour-stromal interactions in breast cancer: the role of stroma in tumourigenesis. Tumour Biol.26(4), 173–185 (2005).
   PubMed Web of Science ®Google Scholar
• Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol.1, 119–150 (2006).
   PubMed Web of Science ®Google Scholar
• Brown LF, Guidi AJ, Schnitt SJ et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin. Cancer Res.5(5), 1041–1056 (1999).
   PubMed Web of Science ®Google Scholar
• Black MM, Kerpe S, Speer FD. Lymph node structure in patients with cancer of the breast. Am. J. Pathol.29(3), 505–521 (1953).
   PubMed Web of Science ®Google Scholar
• Whitford P, Alam SM, George WD, Campbell AM. Flow cytometric analysis of tumour-draining lymph nodes in breast cancer patients. Eur. J. Cancer28(2–3), 350–356 (1992).
   PubMedGoogle Scholar
• Morton BA, Ramey WG, Paderon H, Miller RE. Monoclonal antibody-defined phenotypes of regional lymph node and peripheral blood lymphocyte subpopulations in early breast cancer. Cancer Res.46(4 Pt 2), 2121–2126 (1986).
   PubMed Web of Science ®Google Scholar
• Coronella-Wood JA, Hersh EM. Naturally occurring B-cell responses to breast cancer. Cancer Immunol. Immunother.52(12), 715–738 (2003).
   PubMed Web of Science ®Google Scholar
• Lee AH, Happerfield LC, Bobrow LG, Millis RR. Angiogenesis and inflammation in invasive carcinoma of the breast. J. Clin. Pathol.50(8), 669–673 (1997).
   PubMed Web of Science ®Google Scholar
• Bilik R, Mor C, Hazaz B,Moroz C. Characterization of T-lymphocyte subpopulations infiltrating primary breast cancer. Cancer Immunol. Immunother.28(2), 143–147 (1989).
   PubMed Web of Science ®Google Scholar
• Hussein MR, Hassan HI. Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations. J. Clin. Pathol.59(9), 972–977 (2006).
   PubMed Web of Science ®Google Scholar
• Dorn C, Knobloch C, Kupka M, Morakkabati-Spitz N, Schmolling J. Paraneoplastic neurological syndrome: patient with anti-Yo antibody and breast cancer: a case report. Arch. Gynecol. Obstet.269(1), 62–65 (2003).
   PubMedGoogle Scholar
• Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann. Neurol.53(5), 580–587 (2003).
   PubMed Web of Science ®Google Scholar
• Tomkiel JE, Alansari H, Tang N et al. Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer. Clin. Cancer Res.8(3), 752–758 (2002).
   PubMed Web of Science ®Google Scholar
• Fernandez-Madrid F, Tang N, Alansari H et al. Autoantibodies to annexin XI-A and other autoantigens in the diagnosis of breast cancer. Cancer Res.64(15), 5089–5096 (2004).
   PubMed Web of Science ®Google Scholar
• Frenkel K, Karkoszka J, Glassman T et al. Serum autoantibodies recognizing 5-hydroxymethyl-2´-deoxyuridine, an oxidized DNA base, as biomarkers of cancer risk in women. Cancer Epidemiol. Biomarkers Prev.7(1), 49–57 (1998).
   PubMed Web of Science ®Google Scholar
• Lu H, Goodell V, Disis ML. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J. Proteome Res.7(4), 1388–1394 (2008).
   PubMed Web of Science ®Google Scholar
• Gourevitch MM, von Mensdorff-Pouilly S, Litvinov SV et al. Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Br. J. Cancer72(4), 934–938 (1995).
   PubMed Web of Science ®Google Scholar
• von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P et al. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur. J. Cancer32A(8), 1325–1331 (1996).
   PubMed Web of Science ®Google Scholar
• Lubin R, Zalcman G, Bouchet L et al. Serum p53 antibodies as early markers of lung cancer. Nat. Med.1(7), 701–702 (1995).
   PubMed Web of Science ®Google Scholar
• McNeel DG, Nguyen LD, Storer BE et al. Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. J. Urol.164(5), 1825–1829 (2000).
   PubMed Web of Science ®Google Scholar
• Muller M, Meyer M, Schilling T et al. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers. Int. J. Oncol.29(4), 973–980 (2006).
   PubMed Web of Science ®Google Scholar
• Molina R, Barak V, van Dalen A et al. Tumor markers in breast cancer – European Group on Tumor Markers recommendations. Tumour Biol.26(6), 281–293 (2005).
   PubMed Web of Science ®Google Scholar
• Cho H, Hur HW, Kim SW et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol. Immunother.58(1), 15–23 (2009).
   PubMed Web of Science ®Google Scholar
• Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil–lymphocyte ratio as a prognostic factor in colorectal cancer. J. Surg. Oncol.91(3), 181–184 (2005).
   PubMed Web of Science ®Google Scholar
• Papa A, Emdin M, Passino C et al. Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease. Clin. Chim. Acta395(1–2), 27–31 (2008).
   PubMed Web of Science ®Google Scholar
• Zahorec R. Ratio of neutrophil to lymphocyte counts – rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl. Lek. Listy102(1), 5–14 (2001).
   PubMedGoogle Scholar
• Asworth TR. A case of cancer in which cells similar to those in tumors were seen in the blood after death. Aust. Med. J.14, 146–149 (1869).
   Google Scholar
• Lacroix M. Significance, detection and markers of disseminated breast cancer cells. Endocr. Relat. Cancer13(4), 1033–1067 (2006).
   PubMed Web of Science ®Google Scholar
• Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett.253(2), 180–204 (2007).
   PubMed Web of Science ®Google Scholar
• Pusztai L, Cristofanilli M, Paik S. New generation of molecular prognostic and predictive tests for breast cancer. Semin. Oncol.34(2 Suppl. 3), S10–S16 (2007).
   PubMed Web of Science ®Google Scholar
• Slade MJ, Coombes RC. The clinical significance of disseminated tumor cells in breast cancer. Nat. Clin. Pract. Oncol.4(1), 30–41 (2007).
   PubMedGoogle Scholar
• Ntoulia M, Stathopoulou A, Ignatiadis M et al. Detection of mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. Clin. Biochem.39(9), 879–887 (2006).
   PubMed Web of Science ®Google Scholar
• Hayes DF, Cristofanilli M, Budd GT et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res.12(14 Pt 1), 4218–4224 (2006).
   PubMed Web of Science ®Google Scholar
• Ignatiadis M, Xenidis N, Perraki M et al. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J. Clin. Oncol.25(33), 5194–5202 (2007).
   PubMed Web of Science ®Google Scholar
• Xenidis N, Markos V, Apostolaki S et al. Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. Ann. Oncol.18(10), 1623–1631 (2007).
   PubMed Web of Science ®Google Scholar
• Xenidis N, Perraki M, Kafousi M et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J. Clin. Oncol.24(23), 3756–3762 (2006).
   PubMed Web of Science ®Google Scholar
• Mikhitarian K, Martin RH, Ruppel MB et al. Detection of mammaglobin mRNA in peripheral blood is associated with high grade breast cancer: interim results of a prospective cohort study. BMC Cancer8, 55 (2008).
   PubMedGoogle Scholar
• Nakagawa T, Martinez SR, Goto Y et al. Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes. Clin. Cancer Res.13(14), 4105–4110 (2007).
   PubMed Web of Science ®Google Scholar
• Reinholz MM, Nibbe A, Jonart LM et al. Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer. Clin.Cancer Res.11(10), 3722–3732 (2005).
   PubMed Web of Science ®Google Scholar
• Chen CC, Hou MF, Wang JY et al. Simultaneous detection of multiple mRNA markers CK19, CEA, c-Met, Her2/neu and hMAM with membrane array, an innovative technique with a great potential for breast cancer diagnosis. Cancer Lett.240(2), 279–288 (2006).
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet357(9255), 539–545 (2001).
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature454(7203), 436–444 (2008).
   PubMed Web of Science ®Google Scholar
• Grivennikov S, Karin M. Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell13(1), 7–9 (2008).
   PubMed Web of Science ®Google Scholar
• Karin M. Nuclear factor-κB in cancer development and progression. Nature441(7092), 431–436 (2006).
   PubMed Web of Science ®Google Scholar
• Langowski JL, Zhang X, Wu L et al. IL-23 promotes tumour incidence and growth. Nature442(7101), 461–465 (2006).
   PubMed Web of Science ®Google Scholar
• Szlosarek PW, Balkwill FR. Tumour necrosis factor α: a potential target for the therapy of solid tumours. Lancet Oncol.4(9), 565–573 (2003).
   PubMed Web of Science ®Google Scholar
• Voronov E, Shouval DS, Krelin Y et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl Acad. Sci. USA100(5), 2645–2650 (2003).
   PubMed Web of Science ®Google Scholar
• Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol.7(1), 41–51 (2007).
   PubMed Web of Science ®Google Scholar
• Tisdale MJ. Cachexia in cancer patients. Nat. Rev. Cancer2(11), 862–871 (2002).
   PubMed Web of Science ®Google Scholar
• Tisdale MJ. Biology of cachexia. J. Natl Cancer Inst.89(23), 1763–1773 (1997).
   PubMed Web of Science ®Google Scholar
• Li YP, Schwartz RJ, Waddell ID, Holloway BR, Reid MB. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-κB activation in response to tumor necrosis factor α. FASEB J.12(10), 871–880 (1998).
   PubMed Web of Science ®Google Scholar
• Acharyya S, Ladner KJ, Nelsen LL et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J. Clin. Invest.114(3), 370–378 (2004).
   PubMed Web of Science ®Google Scholar
• Wyke SM, Tisdale MJ. NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin proteasome system in skeletal muscle. Br. J. Cancer92(4), 711–721 (2005).
   PubMed Web of Science ®Google Scholar
• Boddaert MS, Gerritsen WR, Pinedo HM. On our way to targeted therapy for cachexia in cancer? Curr. Opin. Oncol.18(4), 335–340 (2006).
   PubMed Web of Science ®Google Scholar
• Adzic M, Niciforovic A, Vucic V et al. Systemic NF-κB activation in blood cells of breast cancer patients. Redox Rep.11(1), 39–44 (2006).
   PubMedGoogle Scholar
• Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clin. Chem.52(3), 345–351 (2006).
   PubMed Web of Science ®Google Scholar
• Borgono CA, Grass L, Soosaipillai A et al. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res.63(24), 9032–9041 (2003).
   PubMed Web of Science ®Google Scholar
• Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem.48(8), 1296–1304. (2002).
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhang S, Yu J, Liu J, Zheng S. SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer. Breast14(4), 250–255 (2005).
   PubMed Web of Science ®Google Scholar
• Shi L, Shi L, Reid LH et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol.24(9), 1151–1161 (2006).
   PubMed Web of Science ®Google Scholar
• Canales RD, Luo Y, Willey JC et al. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat. Biotechnol.24(9), 1115–1122 (2006).
   PubMed Web of Science ®Google Scholar
• Buyse M, Loi S, van’t Veer L et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst.98(17), 1183–1192 (2006).
   PubMed Web of Science ®Google Scholar
• van de Vijver MJ, He YD, van’t Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med.347(25), 1999–2009 (2002).
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med.351(27), 2817–2826 (2004).
   PubMed Web of Science ®Google Scholar
• Van’t Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature415(6871), 530–536. (2002).
   PubMed Web of Science ®Google Scholar
• Habel LA, Shak S, Jacobs MK et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res.8(3), R25 (2006).
   PubMed Web of Science ®Google Scholar
• Perou CM, Jeffrey SS, van de Rijn M et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc. Natl Acad. Sci. USA96(16), 9212–9217 (1999).
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature406(6797), 747–752 (2000).
   PubMed Web of Science ®Google Scholar
• Ma XJ, Hilsenbeck SG, Wang W et al. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J. Clin. Oncol.24(28), 4611–4619 (2006).
   PubMed Web of Science ®Google Scholar
• Ma XJ, Wang Z, Ryan PD et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell5(6), 607–616 (2004).
   PubMed Web of Science ®Google Scholar
• Loi S, Haibe-Kains B, Desmedt C et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J. Clin. Oncol.25(10), 1239–1246 (2007).
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl Cancer Inst.98(4), 262–272 (2006).
   PubMed Web of Science ®Google Scholar
• Kim SJ, Dix DJ, Thompson KE et al. Effects of storage, RNA extraction, genechip type, and donor sex on gene expression profiling of human whole blood. Clin. Chem.53(6), 1038–1045 (2007).
   PubMed Web of Science ®Google Scholar
• Bieli C, Frei R, Schickinger V et al. Gene expression measurements in the context of epidemiological studies. Allergy63(12), 1633–1636 (2008).
   PubMed Web of Science ®Google Scholar
• Fan H, Hegde PS. The transcriptome in blood: challenges and solutions for robust expression profiling. Curr. Mol. Med.5(1), 3–10 (2005).
   PubMed Web of Science ®Google Scholar
• Dumeaux V, Lund E,Børresen-Dale AL. Comparison of globin RNA processing methods for genome-wide transcriptome analysis from whole-blood. Biomark. Med.2, 11–21 (2008).
   PubMed Web of Science ®Google Scholar
• Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J. Lab. Clin. Med.147(3), 126–132 (2006).
   PubMed Web of Science ®Google Scholar
• Whitney AR, Diehn M, Popper SJ et al. Individuality and variation in gene expression patterns in human blood. Proc. Natl Acad. Sci. USA100(4), 1896–1901 (2003).
   PubMed Web of Science ®Google Scholar
• Eady JJ, Wortley GM, Wormstone YM et al. Variation in gene expression profiles of peripheral blood mononuclear cells from healthy volunteers. Physiol. Genomics22(3), 402–411 (2005).
   PubMed Web of Science ®Google Scholar
• Dumeaux V, Lund E, Børresen-Dale A-L. Comparison of globin RNA processing methods for genome-wide transcriptome analysis from whole-blood. Biomark. Med.2, 11–21 (2008).
   PubMed Web of Science ®Google Scholar
• Lampe JW, Stepaniants SB, Mao M et al. Signatures of environmental exposures using peripheral leukocyte gene expression: tobacco smoke. Cancer Epidemiol. Biomark. Prev.13(3), 445–453 (2004).
   PubMed Web of Science ®Google Scholar
• Ryder MI, Hyun W, Loomer P, Haqq C. Alteration of gene expression profiles of peripheral mononuclear blood cells by tobacco smoke: implications for periodontal diseases. Oral Microbiol. Immunol.19(1), 39–49 (2004).
   PubMedGoogle Scholar
• Dumeaux V, Johansen J, Borresen-Dale AL, Lund E. Gene expression profiling of whole-blood samples from women exposed to hormone replacement therapy. Mol. Cancer Ther.5(4), 868–876 (2006).
   PubMed Web of Science ®Google Scholar
• Wang Z, Neuburg D, Li C et al. Global gene expression profiling in whole-blood samples from individuals exposed to metal fumes. Environ. Health Perspect.113(2), 233–241 (2005).
   PubMed Web of Science ®Google Scholar
• Forrest MS, Lan Q, Hubbard AE et al. Discovery of novel biomarkers by microarray analysis of peripheral blood mononuclear cell gene expression in benzene-exposed workers. Environ. Health Perspect.113(6), 801–807 (2005).
   PubMed Web of Science ®Google Scholar
• Amundson SA, Do KT, Shahab S et al. Identification of potential mRNA biomarkers in peripheral blood lymphocytes for human exposure to ionizing radiation. Radiat. Res.154(3), 342–346 (2000).
   PubMed Web of Science ®Google Scholar
• Twine NC, Stover JA, Marshall B et al. Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res.63(18), 6069–6075 (2003).
   PubMed Web of Science ®Google Scholar
• Solmi R, Ugolini G, Rosati G et al. Microarray-based identification and RT-PCR test screening for epithelial-specific mRNAs in peripheral blood of patients with colon cancer. BMC Cancer6, 250 (2006).
   PubMed Web of Science ®Google Scholar
• Burczynski ME, Peterson RL, Twine NC et al. Molecular classification of Crohn’s disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells. J. Mol. Diagn.8(1), 51–61 (2006).
   PubMed Web of Science ®Google Scholar
• Osman I, Bajorin DF, Sun T-T et al. Novel blood biomarkers of human urinary bladder cancer. Clin.Cancer Res.12(11 Pt 1), 3374–3380 (2006).
   PubMed Web of Science ®Google Scholar
• Burczynski ME, Twine NC, Dukart G et al. Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin. Cancer Res.11(3), 1181–1189 (2005).
   PubMed Web of Science ®Google Scholar
• Li Y, Elashoff D, Oh M et al. Serum circulating human mRNA profiling and its utility for oral cancer detection. J. Clin. Oncol.24(11), 1754–1760 (2006).
   PubMed Web of Science ®Google Scholar
• Han M, Liew CT, Zhang HW et al. Novel blood-based, five-gene biomarker set for the detection of colorectal cancer. Clin. Cancer Res.14(2), 455–460 (2008).
   PubMed Web of Science ®Google Scholar
• Sharma P, Sahni NS, Tibshirani R et al. Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Res.7(5), 634–644 (2005).
   PubMed Web of Science ®Google Scholar
• Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev. Cell11(4), 441–450 (2006).
   PubMed Web of Science ®Google Scholar
• Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nat. Rev. Mol. Cell Biol.9(3), 219–230 (2008).
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature435(7043), 834–838 (2005).
   PubMed Web of Science ®Google Scholar
• Iorio MV, Ferracin M, Liu CG et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res.65(16), 7065–7070 (2005).
   PubMed Web of Science ®Google Scholar
• Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA105(30), 10513–10518 (2008).
   PubMed Web of Science ®Google Scholar